Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue

Glioblastoma (GBM) is the most lethal intracranial tumor. Sequencing technologies have supported personalized therapy for precise diagnosis and optimal treatment of GBM by revealing clinically actionable molecular characteristics. Although accumulating sequence data from brain tumors and matched normal tissues have facilitated a comprehensive understanding of genomic features of GBM, these in silico evaluations could gain more biological credibility when they are verified with in vitro and in vivo models. From this perspective, GBM cell lines with whole exome sequencing (WES) datasets of matched tumor tissues and normal blood are suitable biological platforms to not only investigate molecular markers of GBM but also validate the applicability of druggable targets. Here, we provide a complete WES dataset of 26 GBM patient-derived cell lines along with their matched tumor tissues and blood to demonstrate that cell lines can mostly recapitulate genomic profiles of original tumors such as mutational signatures and copy number alterations.

Automated summary

Glioblastoma (GBM) is a deadly intracranial tumor. Sequencing technologies have helped in personalized therapy for GBM, but in vitro and in vivo models are needed to validate in silico evaluations of genomic features. GBM cell lines with whole exome sequencing (WES) datasets of matched tumor tissues and blood can be used to investigate molecular markers and validate druggable targets. A complete WES dataset of 26 GBM patient-derived cell lines along with their matched tumor tissues and blood is provided to show that cell lines can largely recapitulate genomic profiles of original tumors.